Inovio reports positive interim results from Phase I/II hepatitis study -
INO: Positive Results from Ph I/II Study of DNA Vaccine for Hepatitis C -
DNA Vaccine Company Inovio Biomedical Reports Third Quarter 2008 Financial Results -
INO: To Present At BIO Investor Conference @ 19:45 ET [delayed] -
INO: To Present At BIOCOM Investor Conference @ 14:00 ET [delayed] -
INO: Merger Partner VGX Pharmaceuticals Awarded $23.5M NIH Contract -
INO: Awarded 4933K US Army Contract for DNA Vaccine Research -
Inovio reports positive preclinical results of DNA-based cancer vaccine -
INO: Positive Preclinical Results for DNA-Based Cancer Vaccines -
Inovio Biomedical expands electroporation license with IAVI -
INO: Expansion of License Agreement w/International AIDS Vaccine Initiative -
Therapeutic DNA Vaccine Company Inovio Biomedical Reports Second Quarter 2008 Financial Results -
Vista Partners Updates Coverage on Inovio Biomedical Corporation (Amex: INO); $3.57 Price Target -
Inovio's DNA vaccine found to be effective against avian flu -
Inovio Biomedical to Highlight Electroporation-Based DNA Vaccine Delivery at Scientific Conferences -
Inovio and VGX sign merger agreement -
Inovio Biomedical and VGX Pharmaceuticals Sign Merger Agreement -
INO: Additional Interim Results from Phase I/II Study of ChronVac-C(R) -